Luminex Announces Executive Management Changes

  
    
  
  
    
      Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed 
      solutions, today announced the following executive management 
      organizational changes effective March 1, 2008. Randel S. Marfin has 
      been named to the new position of vice president of strategic 
      development, Gregory J. Gosch has been named vice president of the 
      Luminex Bioscience Group and Darin Leigh has been named vice president 
      of sales and marketing.
    
    
      “We are excited about the growth of Luminex 
      and the success of xMAP® technology in our 
      targeted market segments. These executive changes are in response to our 
      Company’s growth and will help us execute as 
      we continue on our anticipated growth trajectory,” 
      said Patrick J. Balthrop, president and chief executive officer of 
      Luminex. “The changes were made to help us 
      explore new applications for xMAP Technology, expand our business, and 
      increase our market share in diagnostics and life science research.”
    
    
      Strategic Development
    
    
      In the newly-created position of vice president of strategic 
      development, Mr. Marfin will be responsible for identifying and building 
      business growth plans that will allow Luminex to access and penetrate 
      new high-value growth markets for our multiplexing technology. Mr. Marfin’s 
      initial focus will be in food safety and animal health, an area that 
      Luminex has entered with a recently announced collaboration with Tyson 
      Foods.
    
    
      Mr. Marfin joined Luminex in June 1998 and previously served as vice 
      president of the Luminex Bioscience Group. He also formerly served as 
      vice president, sales and business development.
    
    
      Luminex Bioscience Group
    
    
      Mr. Gosch will replace Mr. Marfin as vice president of the Luminex 
      Bioscience Group (LBG), which develops and markets innovative and novel 
      testing applications based on xMAP Technology. Since its creation in 
      2005, the Luminex Bioscience Group has launched unique products, 
      including a pneumococcal assay that can test for the 14 most common 
      pneumococcal serotypes, and the FlexmiR™, line 
      of microRNA products.
    
    
      As vice president of the Luminex Bioscience Group, Mr. Gosch will 
      oversee the group’s business development, 
      assay product development, and manufacturing and commercial strategies.
    
    
      Sales and Marketing
    
    
      Darin Leigh was previously senior director of sales and marketing for 
      diagnostics at Luminex.
    
    
      Mr. Leigh will replace Mr. Gosch as vice president of sales and 
      marketing. Mr. Leigh will manage Luminex’s 
      worldwide sales and marketing efforts and will be responsible for 
      driving increased adoption of Luminex’s xMAP 
      Technology across life science research and diagnostic markets.
    
    
      Before joining Luminex, Mr. Leigh held a number of positions at Abbott 
      Laboratories in Europe and in the United States. Between 2001 and 2005 
      these included positions in global marketing, with responsibilities for 
      the launch of the Abbott Architect immunochemistry systems. Previously, 
      he held positions in sales with laboratory suppliers in the United 
      Kingdom. Mr. Leigh holds a degree in Medical Laboratory Sciences from 
      the University of London.
    
    
      About Luminex Corporation
    
    
      Luminex Corporation develops, manufactures and markets proprietary 
      biological testing technologies with applications throughout the 
      diagnostic and life sciences industries. The Company's xMAP® 
      multiplex solutions include an open-architecture, multi-analyte 
      technology platform that delivers fast, accurate and cost-effective 
      bioassay results to markets as diverse as pharmaceutical drug discovery, 
      clinical diagnostics and biomedical research, including the genomics and 
      proteomics research markets. The Company's xMAP technology is sold 
      worldwide and is already in use in leading clinical laboratories as well 
      as major pharmaceutical, diagnostic and biotechnology companies. Further 
      information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.
    
    
      Statements made in this release that express Luminex's or 
      management's intentions, plans, beliefs, expectations or predictions of 
      future events are forward-looking statements. The words "believe," 
      "expect," "intend," "estimate," "anticipate," "will," "could," "should" 
      and similar expressions are intended to further identify such 
      forward-looking statements for purposes of the Private Securities 
      Litigation Reform Act of 1995. It is important to note that the 
      Company's actual results or performance could differ materially from 
      those anticipated or projected in such forward-looking statements. 
      Factors that could cause Luminex's actual results or performance to 
      differ materially include risks and uncertainties relating to, among 
      others, market demand and acceptance of Luminex's products, the 
      Company's dependence on strategic partners for development, 
      commercialization and distribution of products, concentration of the 
      Company's revenue in a limited number of strategic partners, 
      fluctuations in quarterly results due to a lengthy and unpredictable 
      sales cycle and bulk purchases of consumables, Luminex's ability to 
      scale manufacturing operations and manage operating expenses, gross 
      margins and inventory levels, potential shortages of components, 
      competition, the timing of regulatory approvals, the implementation, 
      including any modification, of the Company's strategic operating plans, 
      risks and uncertainties associated with implementing our acquisition 
      strategy and the ability to integrate acquired companies or selected 
      assets into our consolidated business operations, as well as the risks 
      discussed under the heading "Risk Factors" in Luminex's Reports on Forms 
      10-K and 10-Q, as filed with the Securities and Exchange Commission. The 
      forward-looking statements contained herein represent the judgment of 
      Luminex as of the date of this press release, and Luminex expressly 
      disclaims any intent, obligation or undertaking to release publicly any 
      updates or revisions to any forward- looking statements to reflect any 
      change in Luminex's expectations with regard thereto or any change in 
      events, conditions or circumstances on which any such statements are 
      based.